Clinical Trial Update: Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating interleukin-2 gene therapy or methotrexate in patients with recurrent or refractory stage III/IV head and neck cancer; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Interleukin-2 gene (interleukin-2 gene therapy)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED